We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
- Authors
Weickhardt, A J; Williams, D S; Lee, C K; Chionh, F; Simes, J; Murone, C; Wilson, K; Parry, M M; Asadi, K; Scott, A M; Punt, C J A; Nagtegaal, I D; Price, T J; Mariadason, J M; Tebbutt, N C
- Abstract
Background:Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorectal cancer. We analysed the protein expression levels of vascular endothelial growth factor (VEGF) ligands and receptors to determine their prognostic and predictive effects.Methods:We graded expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-R1, and VEGF-R2 to assess whether overexpression predicted bevacizumab resistance in samples from 268 of 471 patients randomised to capecitabine (C), capecitabine and bevacizumab (CB), or CB and mitomycin (CBM) in the MAX trial and extended the analysis to the CAIRO-2 population.Results:Patients with low expression of VEGF-D (0, 1+) benefited from bevacizumab treatment (PFS hazard ratio (HR) (C vs CB+CBM), 0.21; 95% CI, 0.08-0.55; overall survival (OS) HR, 0.35; 95% CI, 0.13-0.90). Patients with higher VEGF-D expression received less benefit (VEGF-D 2+ PFS HR, 0.67; 95% CI, 0.45-1.00; OS HR, 0.82; 95% CI, 0.52-1.30; VEGF-D 3+ PFS HR, 0.77; 95% CI, 0.50-1.17; OS HR, 1.28; 95% CI, 0.79-2.09) (P interaction <0.05). In CAIRO-2, there was no difference in PFS or OS according to VEGF-D expression.Conclusions:The predictive value of VEGF-D expression for bevacizumab may depend on the chemotherapy backbone used. Further evaluation is required before clinical utilisation.
- Subjects
BEVACIZUMAB; VASCULAR endothelial growth factors; ANTINEOPLASTIC agents; COLON cancer; BIOMARKERS
- Publication
British Journal of Cancer, 2015, Vol 113, Issue 1, p37
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/bjc.2015.209